Porcine factor VIII has been used historically for treating hemophilia A patients with inhibitors due to its low cross-reactivity with anti-human fVIII antibodies, which results in a higher level of activity in comparison with human fVIII [39–41]. Here, F8 is linked to hemophilia A.